NEW YORK (GenomeWeb News) – Roche said this week that a paper published in the most recent issue of the Journal of Infectious Disease demonstrated that ultra-deep sequencing with 454 Life Sciences' sequencing system was able to identify low-frequency hepatitis B virus drug-resistant mutations in infected samples, including mutations that were undetected using standard direct PCR sequencing methods.